Ignite Creation Date:
2024-05-06 @ 1:45 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01881217
Status:
COMPLETED
Last Update Posted:
2017-09-14
First Post:
2013-06-17
Brief Title:
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced Refractory Solid Tumors
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Open-label Phase I Dose-escalation Study to Characterize the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label non-randomized Phase I dose-escalation study designed to assess the safety tolerability pharmacokineticsPK pharmacodynamics PD and tumor response profile of BAY1179470 in subjects with advanced refractory solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None